MRNA

SEC source: 0001127602-21-012317 · form4.xml · derivative · entry 3

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 599,822

Underlying: Common Stock · 5,000 shares

Expires 2027-08-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020.

F2 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

SEC source: 0001127602-21-012317 · form4.xml · nonDerivative · entry 2

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020.

SEC source: 0001127602-21-012317 · form4.xml · nonDerivative · entry 1

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020.

SEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 10

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.

Disclosed balance after: 11,234,340

F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans.

F12 · shares: Represents 469 shares sold by Flagship Fund IV and 89 shares sold by Flagship Fund IV-Rx.

F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 9

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.

Disclosed balance after: 11,234,898

F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans.

F11 · shares: Represents 5,552 shares sold by Flagship Fund IV and 1,058 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.12 to $130.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F11 · price: Represents 5,552 shares sold by Flagship Fund IV and 1,058 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.12 to $130.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 8

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.

Disclosed balance after: 11,241,508

F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans.

F10 · shares: Represents 69,923 shares sold by Flagship Fund IV and 13,319 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.12 to $130.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F10 · price: Represents 69,923 shares sold by Flagship Fund IV and 13,319 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.12 to $130.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 7

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.

Disclosed balance after: 11,324,750

F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans.

F9 · shares: Represents 103,635 shares sold by Flagship Fund IV and 19,739 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.12 to $129.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F9 · price: Represents 103,635 shares sold by Flagship Fund IV and 19,739 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.12 to $129.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 6

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.

Disclosed balance after: 11,448,124

F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans.

F8 · shares: Represents 39,372 shares sold by Flagship Fund IV and 7,500 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.04 to $128.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F8 · price: Represents 39,372 shares sold by Flagship Fund IV and 7,500 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.04 to $128.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 5

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.

Disclosed balance after: 11,494,996

F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans.

F7 · shares: Represents 69,348 shares sold by Flagship Fund IV and 13,209 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.03 to $127.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F7 · price: Represents 69,348 shares sold by Flagship Fund IV and 13,209 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.03 to $127.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 4

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.

Disclosed balance after: 11,577,553

F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans.

F6 · shares: Represents 97,762 shares sold by Flagship Fund IV and 18,621 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.03 to $126.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F6 · price: Represents 97,762 shares sold by Flagship Fund IV and 18,621 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.03 to $126.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 3

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.

Disclosed balance after: 11,693,936

F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans.

F5 · shares: Represents 211,298 shares sold by Flagship Fund IV and 40,247 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.03 to $125.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · price: Represents 211,298 shares sold by Flagship Fund IV and 40,247 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.03 to $125.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 2

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.

Disclosed balance after: 11,945,481

F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans.

F4 · shares: Represents 537,331 shares sold by Flagship Fund IV and 102,350 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.03 to $124.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · price: Represents 537,331 shares sold by Flagship Fund IV and 102,350 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.03 to $124.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 1

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.

Disclosed balance after: 12,585,162

F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans.

F2 · shares: Represents 238,812 shares sold by Flagship Fund IV and 45,488 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.03 to $123.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · price: Represents 238,812 shares sold by Flagship Fund IV and 45,488 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.03 to $123.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001127602-21-012320 · form4.xml · nonDerivative · entry 7

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 99,430

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.61 to $135.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-21-012320 · form4.xml · nonDerivative · entry 6

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 99,930

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.54 to $134.54. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-21-012320 · form4.xml · nonDerivative · entry 5

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 103,130

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.51 to $133.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-21-012320 · form4.xml · nonDerivative · entry 4

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 106,136

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.47 to $132.46. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-21-012320 · form4.xml · nonDerivative · entry 3

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 109,051

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.37 to $131.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-21-012320 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 109,751

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $129.24 to $129.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-21-012320 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 110,051

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.23 to $129.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-21-012109 · form4.xml · nonDerivative · entry 3

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 7,484,880

F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019.

F5 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-21-012107 · form4.xml · derivative · entry 3

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,676

Underlying: Common Stock · 6,600 shares

Expires 2029-03-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

SEC source: 0001127602-21-012107 · form4.xml · nonDerivative · entry 2

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 901

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

SEC source: 0001127602-21-012107 · form4.xml · nonDerivative · entry 1

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,501

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

SEC source: 0001127602-21-012027 · form4.xml · derivative · entry 18

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 346,972

Underlying: Common Stock · 5,000 shares

Expires 2026-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

F13 · derivative.exercise_date: 25% of this option vested and became exercisable on February 23, 2017, with the remainder vesting in 12 equal quarterly installments thereafter.

SEC source: 0001127602-21-012027 · form4.xml · nonDerivative · entry 13

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,609,597

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

SEC source: 0001127602-21-012027 · form4.xml · nonDerivative · entry 12

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,614,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

SEC source: 0001127602-21-012025 · form4.xml · derivative · entry 3

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 604,822

Underlying: Common Stock · 5,000 shares

Expires 2027-08-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020.

F2 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

SEC source: 0001127602-21-012025 · form4.xml · nonDerivative · entry 2

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020.

SEC source: 0001127602-21-012025 · form4.xml · nonDerivative · entry 1

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020.

SEC source: 0001127602-21-012109 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,389,868

F2 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020, as amended December 23, 2020.

F3 · price: The reported disposition represents a bona fide charitable gift made by the reporting person.

SEC source: 0001127602-21-012109 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,391,868

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020.

SEC source: 0001127602-21-012027 · form4.xml · derivative · entry 17

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 351,972

Underlying: Common Stock · 5,000 shares

Expires 2026-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

F13 · derivative.exercise_date: 25% of this option vested and became exercisable on February 23, 2017, with the remainder vesting in 12 equal quarterly installments thereafter.

SEC source: 0001127602-21-012027 · form4.xml · derivative · entry 16

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 557,431

Underlying: Common Stock · 10,000 shares

Expires 2023-08-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

F12 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0001127602-21-012027 · form4.xml · nonDerivative · entry 11

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,609,597

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $144.92 to $145.79. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-21-012027 · form4.xml · nonDerivative · entry 10

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,615,397

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.91 to $144.41. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-21-012027 · form4.xml · nonDerivative · entry 9

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,615,683

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $142.88 to $143.79. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-21-012027 · form4.xml · nonDerivative · entry 8

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,616,283

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $141.78 to $142.51 Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-21-012027 · form4.xml · nonDerivative · entry 7

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,617,142

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $140.77 to $141.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-21-012027 · form4.xml · nonDerivative · entry 6

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,618,242

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $139.68 to $140.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-21-012027 · form4.xml · nonDerivative · entry 5

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,619,944

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $138.67 to $139.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-21-012027 · form4.xml · nonDerivative · entry 4

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,621,817

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $137.64 to $138.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-21-012027 · form4.xml · nonDerivative · entry 3

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,623,956

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $136.49 to $137.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-21-012027 · form4.xml · nonDerivative · entry 2

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,624,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

SEC source: 0001127602-21-012027 · form4.xml · nonDerivative · entry 1

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,614,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

SEC source: 0001127602-21-012023 · form4.xml · derivative · entry 3

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,276

Underlying: Common Stock · 6,600 shares

Expires 2029-03-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

SEC source: 0001127602-21-012023 · form4.xml · nonDerivative · entry 2

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 901

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

SEC source: 0001127602-21-012023 · form4.xml · nonDerivative · entry 1

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,501

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

SEC source: 0001127602-21-011821 · form4.xml · derivative · entry 7

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,599

Underlying: Common Stock · 1,199 shares

Expires 2029-03-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F6 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in 12 equal quarterly installments thereafter.

SEC source: 0001127602-21-011821 · form4.xml · nonDerivative · entry 6

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.